Anti-Human GPC3 Antibody (SAA0134)

Catalog No.

FHE84610

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

GPC3, MXR7, GTR2-2, Glypican-3, Intestinal protein OCI-5, OCI5

Concentration

1.1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P51654

Applications

ELISA, FCM, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0134

Dual-Targeted Engineered Bacterial Outer Membrane Vesicles for Hepatocellular Carcinoma Immunotherapy. [FHE84610]

Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor., PMID:40433120

Structural Features of Glypicans and their Impact on Wnt Signaling in Cancer., PMID:40416340

Hepatocellular Carcinoma and Antibody Drug Conjugates: A Systematic Review., PMID:40416124

A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma., PMID:40406146

Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells., PMID:40307410

Dual-antibody functionalized transistor biosensor for specific diagnosis of liver cancer., PMID:40203597

Expression Profiles of Five Common Cancer Membrane Protein Antigens Collected for the Development of Cocktail CAR-T Cell Therapies Applicable to Most Solid Cancer Patients., PMID:40076777

Targeting glypican 3 by immunotoxins: the promise of immunotherapy in hepatocellular carcinoma., PMID:39985417

Generation of Site-Specifically Labeled Affinity Reagents via Use of a Self-Labeling Single Domain Antibody., PMID:39965119

Anti-GPC3 antibody and cell-penetrating peptide CPP44 dual-ligand modified liposomes for targeted delivery of arsenic trioxide in the treatment of hepatocellular carcinoma., PMID:39883090

Computational discovery of co-expressed antigens as dual targeting candidates for cancer therapy through bulk, single-cell, and spatial transcriptomics., PMID:39872360

Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression., PMID:39838375

A proteomic atlas of glypican-3 interacting partners: Identification of alpha-fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancer., PMID:39822733

Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma., PMID:39815170

Single-Cell Transcriptomics Identifies Selective Lineage-Specific Regulation of Genes in Aortic Smooth Muscle Cells in Mice., PMID:39744838

GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target., PMID:39725192

Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy., PMID:39428649

The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential., PMID:39369212

The Inhibitory Effects of Anti-GPC3 Antibody on Wnt/β-Catenin Signaling Pathway as a Biological Therapy in Liver Cancer., PMID:39349719

Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma., PMID:39312187

Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation., PMID:39113871

[Preparation of bacterial outer membrane vesicles with anti-GPC3 single-chain antibody and identification of their targeting effects on hepatocellular carcinoma]., PMID:39044589

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors., PMID:39043602

Ultrasound-Responsive Nanodelivery System of GPC3-Targeting and Sonosensitizer for Visualized Hepatocellular Carcinoma Therapy., PMID:39011387

Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma., PMID:38978570

A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding., PMID:38776682

Extraction-free, immuno-RPA-CRISPR/Cas13a-based one-pot detection of glypican-3 directly from extracellular vesicles., PMID:38438232

Current methods for the detection of glypican-3., PMID:38108085

Exosomes with IR780 and Lenvatinib loaded on GPC3 single-chain scFv antibodies for targeted hyperthermia and chemotherapy in hepatocellular carcinoma therapy., PMID:38058824

A Single-Step Immunocapture Assay to Quantify HCC Exosomes Using the Highly Sensitive Fluorescence Nanoparticle-Tracking Analysis., PMID:37936599

H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy., PMID:37837401

Nanotargeted Cationic Lipid Microbubbles Carrying HSV-TK Gene Inhibit the Development of Subcutaneous Liver Tumor Model After HIFU Ablation., PMID:37815381

Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report., PMID:37763255

Non-coding RNAs in cancer immunotherapy: Predictive biomarkers and targets., PMID:37735815

A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma., PMID:37677989

Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood., PMID:37636242

Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH., PMID:37626430

Prognostic value of S100A4 and Glypican-3 in hepatocellular carcinoma in cirrhotic HCV patients., PMID:37599312

Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy., PMID:37478283

The efficacy and adverse effects of nivolumab and lenvatinib in the treatment of advanced hepatocellular carcinoma., PMID:37114307

Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma., PMID:37103671

Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3., PMID:37048069

Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET., PMID:36997331

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody., PMID:36990507

A novel brick for bispecific antibody construction., PMID:36964928

Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis., PMID:36947402

Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior., PMID:36944188

H-rGO-Pd NPs Nanozyme Enhanced Silver Deposition Strategy for Electrochemical Detection of Glypican-3., PMID:36903516

An inorganic-organic-polymeric nanovehicle for targeting delivery of doxorubicin: Rational assembly, pH-stimulus release, and dual hyperthermia/chemotherapy of hepatocellular carcinoma., PMID:36871489

Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC., PMID:36691969

Document Download

Anti-Human GPC3 Antibody (SAA0134).pdf